SAS and Carolina partner to accelerate antiviral drug development
Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI).
(UNC.edu)
Related: Campus Connections
New ESPN documentary to highlight Stuart Scott’s life, legacyThe phrase “boo-yah” did not enter the lexicon without resistance. At a time when the sports broadcasting vernacular was bound by the constraints of Merriam...
Fri Nov 28, 2025THT Newsletter: UNC Basketball Feast Week, Football 'Flip Season,' Dylan Mingo Trims List
Happy Thanksgiving! I hope you’re enjoying some well-earned down time with friends, food, family, and Tar Heel sports. This weekend, we’ve got men’s and women’s...
Thu Nov 27, 2025
Pantry Bowl 2025 combats campus hunger
UNC and NC State will again come together on something both can agree on — making sure no student goes to class hungry. The fifth...
Tue Nov 25, 2025
How UNC superfan, Randall Keen, rallies in Carolina blue
Living with ALS hasn’t stopped 64-year-old Randall Keen from cheering for nearly every Tar Heel team — or from teaching his daughter, Avery, what it...
Tue Nov 25, 2025
